Lumida
/SRPT
⌘K
Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

SRPT
$17.22USD↓-0.06%-0.01 today

MARKET CAP

1.8B

P/E (TTM)

20.8x

FWD P/E

11.8x

DAY RANGE

$17 – $18

52W RANGE

$10
$25

AI Summary

Stalk
Sell NowMedium

SRPT remains in a Stage 4 decline with a clear sequence of lower highs and lower lows and EMAs rejecting price rallies. Medium-term bias is bearish, and short-term conditions favor further downside as price fails at EMA and 50 DMA resistance. Execution is Sell Now on rallies into the EMA/50 DMA zone to participate in ongoing downtrend momentum.

  • ↑Q1 net product revenue hit $331M, targeting $1.2–1.4B in 2026 guidance.
  • ↑$748M cash position funds R&D and siRNA pipeline without dilution.
  • ↓Negative profitability metrics and earnings yield highlight efficiency challenges.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a biotechnology company focusing on the development of innovative genetic medicines, primarily targeting rare diseases such as Duchenne muscular dystrophy (DMD). The company is notable for its pioneering work in RNA-targeted therapeutics and its gene therapy product Alevitus, which enjoys a prominent position in the market. As the leader in DMD gene therapies, Sarepta is well-positioned within the expanding landscape of rare disease treatments, focusing on precision medicine and utilizing technology to innovate therapeutic solutions.

Bull says

  • ↑Q1 net product revenue hit $331M, targeting $1.2–1.4B in 2026 guidance.
  • ↑$748M cash position funds R&D and siRNA pipeline without dilution.
  • ↑Advancing siRNA therapies could unlock additional neuromuscular disease markets.
  • ↑FDA accepted sNDAs for AMONDYS 45 and VYONDYS 53, enhancing regulatory momentum.
  • ↑Strong balance sheet quality and high institutional ownership signal confidence.
  • ↑High liquidity and positive sensitivity to oil prices underpin stock stability.

Bear says

  • ↓Negative profitability metrics and earnings yield highlight efficiency challenges.
  • ↓Q1 GAAP loss of $448M and flat revenue revisions underscore growth risks.
  • ↓A patient death linked to Alevitus erodes physician and patient trust.
  • ↓High R&D and SG&A costs ($263M in Q1) pressure cash burn.
  • ↓Analyst cuts and high leverage risk deter potential investors.
  • ↓Low momentum and size factors reflect weak market sentiment.

Investment themes with SRPT

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026neutral

Transcript signals

Bull points

  • In my brief remarks today, I'll share highlights from the quarter and some perspective on how we're thinking about the rest of 2026.
  • In Q1, we reported $400 million of collaboration and other revenues, and consistent with previous guidance, this included $325 million of non-cash collaboration revenue related to Roche declining a program option, as well as $40 million of milestone revenue from the first commercial sale of Levitas in Japan.
  • we are reaffirming our prior revenue and office guidance, as well as our expectation of profitability and to be growing our cash balance from here.

Bear points

  • first quarter total revenues were $731 million, a decrease of 2% compared to Q1 of last year. The decrease in our net product revenues year over year was driven by lower elevative sales and was partially offset by an increase in collaboration and other revenues.
  • total cost of sales for the quarter was $109 million, a decrease of 21% compared to last year, given primarily by lower sales volume.
  • Combined R&D and SGA expenses in the first quarter were $263 million and $224 million on a GAAP and a non-GAAP basis, respectively.
Read full transcript analysis ›